Australian clinical stage biopharmaceutical company: Immuron Ltd (IMRN) (1994)

Immuron Limited (NASDAQ: IMRN, ASX: IMC) was founded in Australia in 1994, and listed on the Australian Securities Exchange in April 1999. The company is headquartered in Victoria, Australia, with 8 full-time employees (5/24/2017). Having a proprietary technology platform, focusing on the development and commercialization of polyclonal antibodies for new immunomodulators, can solve significant unmet medical needs. Immuron specializes in nutrition, medicine and related therapeutic technology products, including oral and GI mucositis, conventional and avian influenza-E. coli traveler’s diarrhea (TD), irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), And anthrax containment.

Immuron Limited

Immuron Ltd (IMRN):

Immuron Limited is a biopharmaceutical company that focuses on the research and development of immunomodulatory polyclonal antibodies, and treats and prevents various diseases through its oral immunoglobulin platform in Australia and internationally.

Immuron Limited operates through two departments: Research and Development (R&D) and HyperImmune Products.

Immuron Limited sells Travelan to prevent travelers’ diarrhea.

Immuron Limited’s main product candidate IMM-124E is in phase II clinical trials for the treatment of non-alcoholic steatohepatitis, severe alcoholic hepatitis and non-alcoholic fatty liver disease.

Immuron is also developing IMM-529, a clinical-stage product for Clostridium difficile infection.

Immuron Limited and Walter Reed Army Institute of Research (Walter Reed Army Institute of Research) signed a research and development cooperation agreement to develop a vaccine for a type of dysentery; and the US Naval Medical Research Center (US Naval Medical Research Center) tested Travelan against Campylobacter and intestinal Reactivity and therapeutic effects of toxigenic E. coli.

Immuron Ltd (IMRN) investment:

Immuron Limited (NASDAQ: IMRN, ASX: IMC) submitted its IPO prospectus on 12/21/2016. The listing date was delayed several times. The most recent plan was to go public on 5/31/2017, but it was finally postponed again. On 6/9/2017, the IPO was finally successful, the issue price was US$9.99, 610,000 shares were issued, and the capital raised was US$6.0939 million, stock code: IMRN.

Notify of
Inline Feedbacks
View all Intels

Private collateral guarantee insurance service: NMI Holdings (NMIH) (2011)

Medical device company: CytoSorbents Corporation (CTSO)